U.S. Capital Markets Stock News

In early March 2026, Qualcomm and its peers pushed back against draft U.S. rules on AI chip export controls, while the company also highlighted new AI, robotics, and 6G initiatives and industry partnerships announced around Mobile World Congress in Barcelona. Despite fresh collaborations in private wireless for utilities and new robotics and edge AI platforms, investors are focused on weakening sales projections and tighter export scrutiny that could limit Qualcomm’s future addressable...

Certara (CERT) is back in focus after its physiologically based pharmacokinetic modeling underpinned the U.S. FDA review of asciminib, with simulations accepted in place of several clinical pharmacology studies for the cancer drug’s new drug application. See our latest analysis for Certara. Despite the FDA validation of its PBPK modeling and a recent earnings update, Certara’s share price return has been weak, with a 30 day share price return of 7.23% decline and a 1 year total shareholder...

EMCOR Group (EME) is back in focus after reporting fourth quarter and full year 2025 results, with sales and net income above the prior year, along with new 2026 revenue and earnings guidance. See our latest analysis for EMCOR Group. The strong full year results and higher 2026 guidance come after a period of firm momentum, with a 90 day share price return of 13.18% and a 1 year total shareholder return of 88.42%. However, the recent 1 day and 7 day share price declines suggest investors are...

Blue Bird’s Micro Bird buyout and earnings momentum come into focus Blue Bird (BLBD) has drawn fresh attention after moving to buy out Girardin’s 50% stake in the Micro Bird joint venture, while recent earnings results and an updated revenue and EBITDA outlook have also been in focus for investors. See our latest analysis for Blue Bird. At a share price of US$54.74, Blue Bird has recently seen a 10.16% 1 month share price return and a 17.07% year to date share price return. Its 1 year total...

In early March 2026, Genevant Sciences, Arbutus Biopharma and Moderna reached a global settlement of up to US$2.25 billion over alleged unauthorized use of lipid nanoparticle delivery technology in Moderna’s COVID-19 vaccines, with US$950 million due upfront and the remainder contingent on the outcome of a Section 1498 appeal. The agreement not only ends all related litigation but also grants Moderna a global non-exclusive license for infectious disease applications, clarifying its freedom...

Ituran Location and Control recently reported Q4 2025 and full-year 2025 results showing higher revenue and net income year over year, and the board approved a US$1.50 per-share cash dividend totaling about US$30,000,000, payable on April 16, 2026 to shareholders of record on March 30, 2026 at a reduced 20% withholding tax rate. Alongside these results, Ituran was selected to deliver Stellantis’s Connect Fiat program for the Fiat Strada on an initially three-year term, marking a deeper role...

In early March 2026, Lincoln National reported its sixth consecutive quarter of growth in adjusted operating income, with management highlighting broad-based strength across Group Protection, Annuities, Retirement Plan Services, and Life Insurance on its Q4 2025 earnings call. At the same time, analysts at firms such as Wells Fargo and Morgan Stanley reiterated positive views on the insurer, emphasizing improving free cash flow, lower leverage, and clearer prospects for future capital...

In early March 2026, John Wiley & Sons, Inc. reported fiscal third-quarter sales of US$410.04 million, returning to a net income of US$29.68 million and positive earnings per share from continuing operations after a loss in the same period a year earlier. Separately, OpenEvidence announced a partnership to integrate a wide portfolio of Wiley’s peer-reviewed medical and scientific content into its point-of-care platform, highlighting how Wiley’s research assets are being embedded in...

Lennox International (NYSE:LII) has entered the North American water heating market through a joint venture with Ariston Group. The partnership is launching a new line of water heaters, adding to Lennox's existing product portfolio. The move expands Lennox's dealer network and allows contractors to offer integrated HVAC and water heating solutions. Lennox International, best known for residential and commercial HVAC systems, is now stepping into water heating, a closely related category...

If you are wondering whether Tenet Healthcare at around US$236.95 is still offering value after a strong run, or if most of the upside is already priced in, this article is here to help you frame that question clearly. The stock has been volatile recently, with a 1% decline over the last 7 days, a 24.3% gain over the last 30 days, an 18.8% return year to date, an 85.9% return over 1 year, and a very large 3 year and 5 year return. This naturally raises questions about risk, sentiment, and...

In early March 2026, Omada Health launched its GLP-1 Flex Care program for employer clients and reported fourth-quarter 2025 revenue of US$75.85 million with net income of US$5.16 million, alongside full-year 2025 revenue of US$260.21 million and reduced annual net loss of US$12.78 million. By combining a cash-pay GLP-1 access model that limits employers’ drug spend with improving profitability metrics, Omada is positioning its virtual care platform as both a cost-control and...

Large investors have been actively reshaping their positions in Turning Point Brands (NYSE:TPB) following the company’s move toward nicotine pouches. Apis Capital Advisors has raised its stake, while Cannell Capital has cut its holdings, with both changes occurring soon after a strong earnings report. These moves highlight differing views on the shift from legacy products to modern oral nicotine and the role of nicotine pouches in TPB’s future. Turning Point Brands, trading at $91.66, has...

IDEX (IEX) has drawn investor attention after recent share price moves, with the stock showing mixed returns over the past month and past 3 months, prompting a closer look at its current valuation setup. See our latest analysis for IDEX. At around $197.90, IDEX’s recent 1 day and 7 day share price declines of 2.67% and 5.52% sit against a 90 day share price return of 11.47% and year to date share price return of 10.52%. Longer multi year total shareholder returns have been more muted, which...

GlobalFoundries (NasdaqGS:GFS) announced a multi billion dollar manufacturing partnership with Renesas Electronics. The agreement focuses on supplying automotive grade chips, particularly microcontrollers used across vehicles. Production is set to begin in the US, with plans for future capacity expansion in other regions. The partnership is framed as a way to support supply chain security for critical automotive semiconductors. For GlobalFoundries, this deal sits at the intersection of its...

In late February, Ares Management filed an omnibus shelf registration covering Class A common stock, preferred stock, debt securities, depositary shares, warrants, purchase contracts, and units, while also participating in a multi‑billion‑dollar unitranche financing backing Thoma Bravo’s acquisition and merger of WWEX Group and Auctane. These developments came as Ares faced increased scrutiny over private credit risks and an earnings miss, highlighting the tension between its expanding...

How Cigna Group’s Recent Performance Sets Up the Valuation Debate Cigna Group (CI) has drawn investor attention after recent share performance that includes a 3.4% one day decline and a 6.3% drop over the past week, sharpening focus on its current valuation and fundamentals. See our latest analysis for Cigna Group. The recent 1 day share price decline and weak 7 day share price return compare with a year to date share price decline of 2.7% and a 1 year total shareholder return decline of...

Ionis Pharmaceuticals (IONS) is back in focus after the US FDA accepted a Priority Review for its supplemental New Drug Application for olezarsen in severe hypertriglyceridemia, placing a key RNA medicine under a tighter regulatory timeline. See our latest analysis for Ionis Pharmaceuticals. Despite the latest FDA Priority Review, Ionis Pharmaceuticals' recent share price momentum has cooled, with a 30 day share price return of 12.88% and a year to date share price return decline of 7.07%,...

What Symbotic’s latest quarter means for investors Symbotic (SYM) reported a fiscal Q1 that featured revenue near US$630 million and margin expansion as more warehouse automation sites moved into steady operations, drawing fresh attention to the stock. See our latest analysis for Symbotic. Despite a stronger fiscal Q1 narrative, Symbotic’s recent share price has been under pressure, with a 1-day share price return of an 8.63% decline and a year-to-date share price return of a 25.07% decline...

With no single headline driving Steel Dynamics (STLD) today, investors are instead weighing its recent performance, including a past 3 months return near 10% and a 1 year total return around 47%. See our latest analysis for Steel Dynamics. At a share price of US$181.61, Steel Dynamics has recently seen a 1 month share price return of about a 9% decline, even though its 1 year total shareholder return is around 47%. This suggests that shorter term momentum looks softer than the longer term...

If you are asking yourself whether Ardelyx at around US$6.19 is attractively priced or not, this article is going to walk through what the current market price might be implying about its value. The share price has seen mixed returns, including a 5.5% decline over the last week and a 16.1% decline over the last month, alongside a 16.8% return over the past year and 73.9% over three years. Year to date performance is around 0.7%, and the 5 year return reflects an 11.2% decline. Recent trading...

Biogen (NasdaqGS:BIIB) and Stoke Therapeutics reported promising clinical results for zorevunersen in Dravet syndrome, with data highlighting durable seizure reductions and cognitive benefits. The zorevunersen findings were published in The New England Journal of Medicine, supporting its potential as a disease modifying therapy for this rare, severe epilepsy. Biogen released new high dose SPINRAZA data for spinal muscular atrophy, including long term safety and efficacy updates. The company...

If you are wondering whether MarketAxess Holdings at around US$186 still reflects its underlying value, this article walks through the key numbers that matter. The stock has had a mixed run, with a 14.6% return over the last 30 days and a 4.2% gain year to date, set against a 9.5% decline over 1 year and deeper falls of 44.1% over 3 years and 62.0% over 5 years. These moves have kept MarketAxess on the radar for investors who follow how electronic bond trading platforms are priced and used,...

If you are wondering whether GDS Holdings is priced attractively today or if the recent share moves have already priced in the story, this article walks through what the numbers are really saying about its valuation. The stock last closed at US$40.87, with a 12.4% return over the past year, a 6.6% gain year to date, and longer term results that include a very large 3 year return alongside a 55.2% decline over 5 years, which can change how investors view both its potential and its...

Willis Lease Finance (WLFC) just paired two expansion themed moves by naming aviation finance veteran Marilyn Gan as Head of Origination, Asia Pacific and completing a six aircraft Dash 8 400 purchase and leaseback with Porter Airlines. See our latest analysis for Willis Lease Finance. Those moves come after a sharp pullback, with a 7 day share price return of 12.32% and a 1 day dip of 3.82%. Over a 90 day period the share price return is 36.31%, and the 3 year total shareholder return is...